Delivery Order SPE2DR25D3301-SPE2DR26F20AW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for supply of Rytary ER (extended-release levodopa-carbidopa) 36.25 mg-145 mg capsules in a quantity of 100 units, with a ceiling value of $12,472.95. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, issued on December 21, 2025, and scheduled for completion by December 22, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,680.89 on October 17, 2025, for the supply of Rytary ER 36.25 mg-145 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and performance scheduled to be completed by October 20, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,935.59 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 48.75 MG-195 MG capsules (100-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $10,441.12 to AmerisourceBergen Drug Corp for Rytary ER (carbidopa-levodopa) extended-release capsules, 48.75 mg-195 mg, in a quantity of 100 units. This award, issued on November 4, 2025, with completion targeted for November 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract utilizes competitive procurement procedures and draws from AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,483.62 to AmerisourceBergen Drug Corp for RYTARY ER 23.75 mg-95 mg capsules (100-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitively awarded transaction. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,013.49 to AmerisourceBergen Drug Corp for the supply of RYTARY ER 36.25 MG-145 MG capsules (100-count) under a firm fixed-price contract. The award was made on September 15, 2025, with an ultimate completion date of September 16, 2025, and does not include a set-aside designation. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $4,577.70 to AmerisourceBergen Drug Corp for Rytary ER (extended-release carbidopa/levodopa) 36.25 mg-145 mg capsules in a quantity of 100 units. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 17, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $18,064.57 to supply Rytary ER 36.25 mg-145 mg capsules (100-count units) for delivery to the Conshohocken, Pennsylvania location. This firm fixed-price delivery order, issued December 10, 2025, with an ultimate completion date of December 11, 2025, represents a competitively awarded non-set-aside contract. The award falls under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $35.4K to AmerisourceBergen Drug Corp for the supply of Rytary ER 48.75 mg-195 mg capsules (100-count units). This contract, executed on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order was competitively awarded and falls...
- The Defense Logistics Agency awarded a delivery order valued at $6,241.31 to AmerisourceBergen Drug Corp for Rytary ER 36.25 mg–145 mg capsules (100-count supply) on June 5, 2025, with completion scheduled for June 6, 2025. This non-set-aside, firm fixed-price delivery order represents pharmaceutical procurement for military healthcare support. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical procurement and holds...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F20AWDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $16,954.94 to AmerisourceBergen Drug Corp for the supply of Rytary ER (23.75 mg-95 mg capsules) in a quantity of 100 units. This competitively awarded, non-set-aside firm fixed price contract is effective through December 31, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child delivery order under its existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion vehicle designated SPE2DX running through December 2026. Rytary ER is an extended-release formulation used in the treatment of Parkinson's disease, reflecting the pharmaceutical distributor's role in supplying specialized neurological medications to support military and federal healthcare systems. As a critical vendor in the DLA Medical Supply Chain, AmerisourceBergen Drug Corp leverages its comprehensive pharmaceutical portfolio and competitive positioning to deliver brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's extensive federal contracting history demonstrates consistent capability in meeting open competition requirements for federal medical procurement across diverse product categories and transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.0k | 12/29/25 |